Navigation Links
Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting

sentations at DDW

Favorable Cross-Resistance Profile of HCV-796 and Boceprevir (SCH-503034) and Enhanced Anti-Replicon Activity Mediated By Combination Treatment; R. Ralston, Monday, May 21, 11:15 a.m., Room 206

Pharmacodynamic Analysis of the Antiviral Activity of the Non-Nucleoside Polymerase Inhibitor, HCV-796, in Combination With Peginterferon Alfa-2b in Treatment-Naive Patients With Chronic HCV; E.S. Maller, Monday, May 21, 2:15 p.m., Room 206

Phase II Study of celgosivir in combination with Peginterferon alfa-2b and ribavirin in chronic hepatitis C genotype 1 nonresponder patients; K.D. Kaita, Monday, May 21, 2:45 p.m., Room 206

    Schering-Plough Sponsored CME Symposium


    "HCV Treatment Decisions: Challenging Issues"

    Monday, May 21, 6:30-8:30 pm, Grand Hyatt Washington,

    Independence Ballroom A, 1000 H Street, NW, Washington, D.C.

This case-based symposium is designed to outline effective management strategies for patients with hepatitis C virus infection. Optimizing HCV patient outcome requires a thorough understanding of the underlying patient and disease factors that influence treatment. Clinical scenarios will be presented, and through the use of case studies, the distinguished faculty will review and discuss current data to illustrate their respective treatment decisions.

About PEGINTRON and REBETOL Combination Therapy

PEGINTRON is approved in the United States for use alone or with ribavirin (800 mg/day) for the treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and who are at least 18 years of age.

WARNING

Alpha interferons, including PEGINTRON, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsen
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
2. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study

Post Your Comments:
(Date:11/6/2009)...-- Facet Solutions, Inc. announced today that it h...s. The acquisition creates an undisputed leadershi...erty and clinical experience in posterior motion p... from lumbar spinal stenosis," stated Facet Soluti...olidation further strengthens Facet Solutions, pos...
(Date:11/6/2009)...tCall/ -- Boston Scientific Corporation (NYSE: BS...nt in principle with the U.S. Department of Justic...s Guidant subsidiary in 2005. The alleged conduct...ific,s 2006 acquisition of Guidant. ,, Boston S...n by the U.S. Attorney,s Office in Minneapolis int...
(Date:11/6/2009)...-- Philips Respironics applauds the efforts of the...to raise awareness about an important public healt...release of the first-ever government study to moni... a milestone in quantifying the size and scope of ...try leader and sleep therapy manufacturer, Philips...
Breaking Medicine Technology:Facet Solutions Acquires Archus Orthopedics 2Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 2Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 3Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 4Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 5Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 6Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 7Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 8Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 9Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 10Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 11Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 12Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 13Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 14Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 15Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 16Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 17Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 2Promising device snags young inventors coveted spot at IShow 8813 1Promising device snags young inventors coveted spot at IShow 8813 2Promising device snags young inventors coveted spot at IShow 8813 3Cogdell Spencer Inc Declares Quarterly Dividend 48744 1Cogdell Spencer Inc Declares Quarterly Dividend 48744 2New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance 12598 1New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance 12598 2New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance 12598 3New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance 12598 4New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance 12598 5
...Nasdaq: MITI ), a biopharmaceutical company devel..., inflammation and autoimmune diseases, today,pres...ation for Cancer,Research (AACR) in San Diego, CA,...ies targeting CD33 and MCSP, for the treatment of .... BiTE antibodies are designed to direct,the body,...
...t,the Texas Heart Institute (THI) at St. Luke,s Ep...ld,s first clinical trial to treat heart attack,pa... better healing and to,prevent congestive heart fa...rt attack., Almost six million Americans have con...ovascular disease that inhibits the heart from,pum...
Other Medicine Technology:Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma 2Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma 3Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma 4Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma 5Texas Heart(R) Institute at St. Luke's Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type 2Texas Heart(R) Institute at St. Luke's Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type 3
(Date:11/8/2009)...tical legislation would strengthen Medicare, impro.... 8 SUMMARY: Yesterda...d critical health care reform legislation that wou...ination by insurance companies that prices million... ,, The Affordable Health Care for America Act...
(Date:11/8/2009)...P Praises House Passage of Health Care Reform Bill...icare, improve coverage for all Americans ,, H...- ,, SUMMARY: Last night the United States H...e reform legislation that would strengthen Medicar...companies that prices millions of Americans out of...
(Date:11/8/2009)... UCW Academy of Health holds open h... Victoria, BC (Vocus) November 8, 2009 -- UCW Acad...reer in British Columbia’s health care indus...esday, November 25, 2009. , ,UCW Academy of Healt...ration, nursing and social services, designs its p...
(Date:11/8/2009)...er Costs and Crushing Taxes Nail Nation,s Job Crea...re/ -- In response to U.S. House passage of the he...ntrepreneurship Council (SBE Council) president &a...ent: ,, "Make no mistake, those voting for H.R...ith higher costs and crushing taxes and penalties....
(Date:11/8/2009)...INGTON, Nov. 7 Tonight ... Health Care for America Act, landmark health refo... access to quality, affordable, stable and secure ...s down on some of the insurance industry,s worst p...icans and cut the deficit by $104 billion over ten...
Breaking Medicine News(10 mins):Health News:AARP NY Praises House Passage of Health Care Reform Bill 2Health News:AARP NY Praises House Passage of Health Care Reform Bill 3Health News:AARP NY Praises House Passage of Health Care Reform Bill 4Health News:AARP Pennsylvania Key Vote News Alert 2Health News:AARP Pennsylvania Key Vote News Alert 3Health News:AARP Pennsylvania Key Vote News Alert 4Health News:College Invites Public to Explore Career Options in Health Care 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 3
...According to the researchers at the University of ...ial for the expression of the neural stem cell gen... stem cells are totipotent cells and can different...e adult eye. Led by Dr. Larysa H. Pevny, an assist...
...It has been found that about 44% of women are vict...y affected their physical and mental health. // Sc...e unclear. The Group Health Cooperative in Seattle...ith colleagues from Harborview Injury Prevention a...
...A study has found that both lesbians and heterosex...tain body odors. // According to a previous study ...es in brain process of odor in both heterosexual a...ir existence in humans is questionable. Researcher...
...Professor Simon Wessely, of the King's Center for ...said that British soldiers returning from Iraq are...archer and his team are examining whether there ha...ent to Iraq and those who had not. In the end they...
...A study published in the British Journal of Clinic... and unwanted pregnancies could be prevented by pr...s they have the advantage of easy access. UK re...family planning clinics and community pharmacies. ...
...Recent research has revealed that several parents ...on their children's develoopment//. Their findi...Sports Medicine. The findings are informed by ...ing. The coaches had all spent an average of 17 ye...
Other Medicine News:Health News:Importance of Gene in Eye Development 2Health News:Research into Intimate Partner Violence 2Health News:Morning-After Pill At The Local Pharmacy Could Prevent Unwanted Pregnancies 2Health News:Morning-After Pill At The Local Pharmacy Could Prevent Unwanted Pregnancies 3Health News:Parents of Junior Athletes do More Harm than Good 2
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
Medicine Products: